Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph early_phase_1
1
20%
Ph phase_2
1
20%
Ph phase_1
2
40%
Ph phase_3
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Not yet recruiting1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (20.0%)
Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)

Trials by Status

completed240%
not_yet_recruiting120%
terminated120%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruitingphase_3

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

NCT07178730
completedphase_2

Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT03480672
completedearly_phase_1

HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer

NCT04188951
terminatedphase_1

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

NCT03637803
unknownphase_1

The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma

NCT04262427

Clinical Trials (5)

Showing 5 of 5 trials
NCT07178730Phase 3

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

Not Yet Recruiting
NCT03480672Phase 2

Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

Completed
NCT04188951Early Phase 1

HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer

Completed
NCT03637803Phase 1

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Terminated
NCT04262427Phase 1

The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5